A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas — escZ-BEAM  

CD20+ Aggressive Non-Hodgkin`s Lymphoma Clinical Trial

Official title: Phase I/II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy With Simultaneous Application of Zevalin and BEAM Followed by Autologous Peripheral Stem Cell Transplantation in Relapsed and Refractory CD 20+ Non-Hodgkin's Lymphoma

Status Completed

Clinical Trial Summary

Phase II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy with simultaneous application of Zevalin and BEAM followed by autologous peripheral stem cell transplantation in relapsed and refractory CD 20+ Non-Hodgkin's lymphoma

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Aggression
• CD20+ Aggressive Non-Hodgkin`s Lymphoma
• Lymphoma
• Lymphoma, Non-Hodgkin
• Primary Non-Hodgkin-Lymphoma
• Refractory Non-Hodgkin-Lymphoma

• NCT number: NCT00521560
• Study type: Interventional
• Source: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
• Status: Completed
• Phase: Phase 2
• Start date: March 2006
• Completion date: August 2012